# This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.

> **NCT00531440** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 256 (actual)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Everolimus (RAD001)

## Key facts

- **NCT ID:** NCT00531440
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2005-08
- **Final completion:** —
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531440, "This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00531440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*